VANCOUVER, British Columbia, April 2 — WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce a strategic partnership with AliveCor, Inc. (“AliveCor”), the global leader in AI-powered personal electrocardiogram (ECG) technology, in which Canadian-registered cardiologists from WELL’s network will provide ECG reviews to Canadian consumers who are users of AliveCor’s ECG technology, offering a “second set of eyes” on their heart health metrics. The collaboration integrates WELL Health’s expanding national network of Canadian-licensed cardiologists with AliveCor’s Kardia solution and services, enabling patients to receive timely, expert clinical interpretation of their heart data from home.
Through the Kardia app, Canadian users can now request a Clinician Review after recording an ECG using a Kardia device. Once submitted, the ECG is evaluated within 24 hours by a Canadian-registered cardiologist from WELL Health’s network. Each review provides a more comprehensive clinical evaluation to confirm or refine the initial AI result from Kardia, along with clear written physician guidance on potential next steps for care.
At the foundation of AliveCor’s technology is clinical AI that is cleared to detect life-threatening cardiac conditions. AliveCor’s Kardia app is powered by Health Canada-licensed AI algorithms capable of instantly detecting three of the most common heart arrhythmias in a 30-second recording. With more than 350 million ECGs recorded to date, Kardia is one of the most clinically validated personal ECG solutions in the world. The Clinician Review service adds a critical human layer to this AI-driven analysis: after Kardia’s AI delivers its initial determination, a Canadian-registered cardiologist from WELL Health’s network provides a comprehensive clinical evaluation, confirming or refining the AI result and offering written physician guidance on next steps. WELL Health is compensated for each cardiologist review performed, generating clinical services revenue while expanding the reach of its specialist physician network into the growing remote cardiac monitoring market.
The service is designed to bridge the gap between personal heart monitoring and specialist care, delivering faster insights at a time when access to cardiology services remains constrained across Canada. Elective cardiology wait times have increased by 53%(1) over the last year, with patients waiting an average of 15.3 weeks for specialist consultation(2). By enabling rapid access to cardiologist expertise, this service aims to support earlier clinical decision-making, reduce unnecessary emergency visits, and provide patients with greater confidence in managing their heart health.
Dina Sergi, CEO of WELL Health Diagnostic Centres, commented, “This partnership pairs the clinical expertise of WELL’s cardiologist network with some of the most advanced AI-powered cardiac monitoring technology in the world. By providing clinician review to AliveCor’s AI-driven analysis, we are helping patients get answers faster, reducing pressure on the healthcare system, and creating a new, scalable clinical services revenue stream for WELL.”
Navneet Malpani, Senior Vice President of Partner Alliances at AliveCor, commented, “AliveCor is committed to delivering the most clinically validated heart care tools to patients worldwide. By partnering with WELL Health, Canada’s leader in modern outpatient care, we are providing our Canadian customers with an essential layer of clinical oversight. Patients can receive expert guidance from a certified cardiologist when they need it most, without having to wait for in-person appointments.”
As part of the partnership, WELL Health will consider opportunities to support the broader adoption of AliveCor’s Kardia remote cardiac monitoring solutions throughout WELL’s national network. This launch represents the first phase of the partnership, with opportunities to expand access to additional services and markets over time. Future phases may include deploying AliveCor’s Kardia 12L, a pocket-sized, AI-powered 12-lead ECG system designed for use in primary care, urgent care, and outpatient settings, directly within WELL’s clinic network, further expanding point-of-care cardiac diagnostic capabilities across Canada.
Footnotes:
- BBD, ‘2025 Canada’s Health Care Wait Times’ published on January 30, 2025.
- Fraser Institute, Waiting Your Turn: Wait Times for Health Care in Canada, 2025 Report, published on December 9, 2025.
WELL HEALTH TECHNOLOGIES CORP.
Per: “Hamed Shahbazi”
Hamed Shahbazi
Chief Executive Officer, Chairman and Director
